The Patent Finder

Vasopharm GmbH

Also on record
Records under this name other than the patents Vasopharm GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Vasopharm GmbH

PatentTitleStatus Expires Confidence
US 10,016,431Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,493,075Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,925,877Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,895,372Solid Pharmaceutical Compositions Comprising Biopterin Derivatives and Uses of Such Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,171,766Methods of Treating Patients Suffering from Brain Injury and Methods of Increasing the Value of the Extended Glasgow Outcome Scale of Patients Suffering from Brain Injury
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,222,238Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Term ended
Term ended Apr 22, 2024 · From the USPTO record
Term endedTerm ended Apr 22, 2024From the USPTO record
US 7,541,3604-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level
Term ended
Term ended Dec 30, 2023 · From the USPTO record
Term endedTerm ended Dec 30, 2023From the USPTO record
US 9,382,252Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Term ended
Term ended Oct 8, 2023 · From the USPTO record
Term endedTerm ended Oct 8, 2023From the USPTO record
US 9,422,289Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species
Term ended
Term ended Oct 8, 2023 · From the USPTO record
Term endedTerm ended Oct 8, 2023From the USPTO record
US 8,236,809Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation
Lapsed on the fee record
Ended Aug 7, 2016 · From the USPTO record
Lapsed on the fee recordEnded Aug 7, 2016From the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited